08:49 AM EDT, 10/30/2024 (MT Newswires) -- Blueprint Medicines ( BPMC ) reported a Q3 loss Wednesday of $0.89 per diluted share, narrowing from a loss of $2.20 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.97.

Revenue for the quarter ended Sept. 30 was $128.2 million, up from $56.6 million a year earlier.

Analysts surveyed by Capital IQ expected $127.5 million.

For 2024, the biopharmaceutical company now expects Ayvakit revenue of $475 million to $480 million, up from its previous projection of $435 million to $450 million. Analysts surveyed by Capital IQ expect product sales of $457.9 million.

The company also reported cash, cash equivalents and investments of $882.4 million as of Sept. 30.

Shares of the company were up more than 9% in recent Wednesday premarket activity.

Price: 90.99, Change: +7.59, Percent Change: +9.10